Dette blev tiltrådt i version 6 (18 april 2008) af Risk Management Planen (RMP) præsenteret i Module 1. 8. 2 i markedsføringstilladelsen med efterfølgende opdateringer af RMP og konfirmeret af GHMP.
Risk Management Plan The MAH commits to performing the studies and additional pharmacovigilance activities detailed in the Pharmacovigilance Plan, as agreed in version 6 (18 April 2008) of the Risk Management Plan (RMP) presented in Module 1.8.2. of the Marketing Authorisation and any subsequent updates of the RMP agreed by the CHMP.